In Segment A, individuals will acquire various doses and schedules of oral ABBV-744 tablet to recognize Harmless dosing regimen. Added contributors will likely be enrolled within the identified monotherapy dosign regimen. In Segment B, individuals will get oral ruxolitinib and ABBV-744 is going to be given as "include-on" therapy. In https://warde433qcm6.blogspothub.com/profile